Project Grant R01DA060889
Award Date
5/15/25
Completion Date
2/28/30
Dollars Obligated
$721K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
This Project Grant award of $424,545.00 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a national survey on naloxone use and access. The goals of this 2-year project are to provide timely evidence on the state of naloxone carrying in the U.S., including monitoring the impact of the recent over-the-counter (OTC) naloxone product approvals. The project will examine barriers to naloxone purchasing and possession, such as...
This Project Grant award of $1,717,104 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a 3-year collaborative effort to adapt, produce, and pilot test a written "Youth Overdose Prevention Toolkit" for use in pediatric healthcare settings. The toolkit will provide clinicians with practical, evidence-based guidance on delivering interventions such as naloxone distribution, take-home drug testing, harm reduction...
This Project Grant award for $144,362.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to evaluate a pharmacist-integrated model of opioid use disorder (OUD) treatment in primary care settings to increase naloxone co-prescribing. The research aims to: 1) describe federal, state, and clinic-level policies and interventions impacting naloxone co-prescribing, 2) investigate care team knowledge and attitudes...
This $197,748 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to develop and pilot an enhanced low-dose buprenorphine initiation (LDI) program to improve treatment outcomes for individuals with opioid use disorder (OUD), especially those using fentanyl. The key objectives of this 4-year project are to: 1) identify barriers to successful LDI completion through qualitative interviews, 2)...
This $1,607,146 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development of community-based technology interventions to encourage drug checking, distribution of harm reduction supplies, and linkage to substance use disorder treatment services. The recipient, NDRI-USA Inc., a non-profit research organization, will use a participatory design process to create multimedia content in English...
This federal Project Grant award of $4,920,000.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to investigate the feasibility, acceptability, and effectiveness of using long-acting injectable naltrexone as a preventive measure for opioid overdose among individuals using stimulants and living with or at risk of HIV. The 4-year study, running from July 1, 2024 to June 30, 2028, will be conducted at the University of...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to address racial disparities in opioid overdose deaths. The $451,962 grant, awarded on July 1, 2024, supports the development and evaluation of a multimodal intervention consisting of an AI-driven texting tool and peer recovery coach (PRC) telephone-based services coordination for Black and Latinx people who use opioids. The key products and services to...
This federal Project Grant award of $431,750, issued by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to identify individual and clinical care factors associated with adolescent drug overdose risk. The key objectives are to: 1) estimate the prevalence of nonfatal drug overdoses in adolescents aged 12-18 and identify high-risk demographic and clinical subgroups, 2) examine behavioral health treatment received...
This federal Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop and evaluate the efficacy of a universal overdose prevention intervention to be delivered in primary care settings for youth ages 13 to 26. The $2,467,574 award will fund a two-phase project. In the first R61 phase, the grantee, Boston Medical Center Corporation, will collaborate with a youth advisory board to develop the...
This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the broader Drug Use and Addiction Research Programs (CFDA 93.279), is supporting the development of a novel overdose reversal agent by Serodopa Therapeutics, Inc. The $1,539,426 award aims to complete formulation development and preclinical testing to prepare an Investigational New Drug (IND) application for the company's intranasal naloxone derivative. This novel agent is designed to more effectively reverse...